• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec23
ZailABS COBENFY® Approved by China's National Medical Products Administration
12:30
Dec22
UBS Gives Anzhi Medicine a Buy Rating
02:30
Dec18
Zai Lab Ltd. Chief Legal Officer Reports Common Stock Disposition
21:35
Dec8
Zailabor Begins First-In-Human Phase 1/1B Study for ZL-1503
12:26
Nov25
Zai Lab's Chief Legal Officer Sells Company Common Stock
21:12
Nov11
UBS Maintains Buy Rating on Zai Lab Ltd With Price Target
00:36

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 116.1 M, Net Income -35.96 M, EPS -0.3263

Zai Lab Limited (ZLAB.US/09688.HK) Q3 2025 Earnings Conference CallZai Lab Limited (ZLAB.US/09688.HK) Q3 2025 Earnings Conference Call
Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 109.98 M, Net Income -40.73 M, EPS -0.3729

May8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 106.49 M, Net Income -48.44 M, EPS -0.4481

Zai Lab Limited (ZLAB.US/09688.HK) Q1 2025 Earnings Conference CallZai Lab Limited (ZLAB.US/09688.HK) Q1 2025 Earnings Conference Call
View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
ASPC
24.010
+78.91%
+10.590
PCLA
0.4050
+74.49%
+0.173
DTCK
0.3951
+66.08%
+0.157
SOPA
1.820
+58.26%
+0.670
ECDA
1.150
+46.50%
+0.365
GAUZ
1.470
+44.12%
+0.450
CELG.RT
0.0698
+39.60%
+0.020
ASPCR
0.2500
+38.89%
+0.070
PAVS
2.170
+37.34%
+0.590
CUE
0.3248
+34.77%
+0.084
View More